Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases - Top-Institutions - MDSpire

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases

  • By

  • Xiangke Xin

  • Wenli Zhang

  • Zhen Li

  • Ruirui Gui

  • Juan Wang

  • Liyun Ji

  • Yanli Zhang

  • Baijun Fang

  • Yongping Song

  • Yingling Zu

  • Jian Zhou

  • February 5, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Bone Marrow Transplantation
    • Clinical Research

  • #2

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Immunotherapy

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Clinical Trials

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Hematology
    • Bone Marrow Transplantation
    • Immunology

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Hematology
    • Stem Cell Transplantation
    • Clinical Research

Original Source(s)

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases

  • by Xiangke Xin, Wenli Zhang, Zhen Li, Ruirui Gui, Juan Wang, Liyun Ji, Yanli Zhang, Baijun Fang, Yongping Song, Yingling Zu, Jian Zhou

  • February 5, 2025

Related Content

Surgical Intervention for Emphysematous Osteomyelitis of the Spine in a Patient with Malnutrition and Anemia: A Unique Case Study

Utilizing Erythrocyte Lifespan as a Predictor for Moderate to Severe Anemia in Patients with Advanced Gastric Cancer Following Anti-Tumor Treatments: A Prospective Investigation

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

  • by

  • December 17, 2025

  • 4 min